Key Insights• According to the research report, "China Heparin Market Outlook, 2031," published by Actual Market Research, the China Heparin Market was valued at more than 1.12 Billion in 2025.• China holds near-total dominance over the global heparin supply chain, producing over 7,300 metric tons of crude heparin annually and supplying over 80% of the world’s porcine intestinal mucosa the foundational raw material for heparin Active Pharmaceutical Ingredients (APIs). China’s export volume of raw heparin and its salts frequently surpasses 100 to 130 metric tons per year, making international pharmaceutical markets heavily reliant on Chinese livestock collection and slaughterhouse integration.• Following severe historical supply shocks like African Swine Fever, leading Chinese heparin manufacturers achieved major technological and industrial breakthroughs by establishing fully integrated, traceable pig-to-drug supply pipelines. High-throughput extraction and automated mucosal recovery facilities have elevated yield efficiency by double digits while meeting stringent regulatory compliance standards required by the U.S. FDA and European Medicines Agency (EMA).• Domestically, the national Volume-Based Procurement (VBP) policy led by China's National Healthcare Security Administration (NHSA) has fundamentally reshaped the market. Centralized bidding for finished dosage forms like enoxaparin and unfractionated heparin has slashed hospital tender prices by upwards of 50% to 70%, accelerating vendor consolidation and forcing domestic producers to push downstream into higher-margin export markets.Market Outlook• To hedge against future swine disease outbreaks and domestic VBP margin compression, Chinese pharmaceutical companies and research institutions are heavily investing in enzymatic synthetic heparin and high-purity LMWH biosimilars. Domestic state funding is accelerating commercial scaling for alternative bio-engineering platforms, aiming to solidify China's position as a next-generation innovator rather than merely a raw mucosa supplier.• The long-term trajectory of the Chinese market will be anchored by a dual-engine strategy: supplying primary bulk API to foreign drugmakers while expanding domestic utilization.

As China's aging population scales and hospital surgical capacity widens under national healthcare expansion plans, local consumption of prefilled Low Molecular Weight Heparin (LMWH) syringes will expand rapidly across cardiac, oncology, and hemodialysis care.• Key policy, industry, and commercial players driving the ecosystem include the NMPA (National Medical Products Administration), the NHSA (National Healthcare Security Administration), and the CCCMHPIE (China Chamber of Commerce for Import & Export of Medicines & Health Products), alongside dominant global suppliers such as Shenzhen Hepalink Pharmaceutical Group, Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Yantai Dongcheng Biochemicals Co., Ltd., Nanjing King-Friend Biochemical Pharmaceutical, and Qianhong Bio-pharma.Market DynamicsDriver: Large and increasingly institutionalized demand for LMWH, particularly enoxaparinChina has a strong hospital-based need for injectable anticoagulants across VTE prevention/treatment, cardiovascular care, surgery and other acute-care applications. A major structural driver is the inclusion of heparin products in China's national volume-based procurement (NVBP) system. In the 8th national centralized procurement round, both enoxaparin sodium injection and nadroparin calcium injection were included, covering 20 specifications in total. This has helped expand access while shifting competition toward high-volume hospital procurement.Challenge: Intense price pressure from centralized procurementThe key challenge for manufacturers is the trade-off between higher volumes and substantially lower procurement prices. China's 8th national procurement round reported an average price reduction of approximately 56% across the selected products, illustrating the scale of pricing pressure generated by volume-based procurement. For heparin manufacturers, this encourages scale, manufacturing efficiency and vertical integration, but can compress margins particularly for companies dependent on finished-dose sales rather than higher-value API or international markets.Trend: Domestic manufacturing and high-quality enoxaparin are becoming increasingly importantChina is moving toward a more domestically competitive heparin ecosystem, with companies such as Hepalink expanding finished-dose enoxaparin manufacturing and participating in national procurement.

Hepalink reports that its enoxaparin sodium injection was the first enoxaparin product selected in China's 8th national centralized procurement, while all SKUs of its Chinese enoxaparin product had passed China's bioavailability-equivalence evaluation in 2020. In 2026, the company reported that its Prolongin enoxaparin ranked first in the renewal procurement covering the first through eighth rounds of the national volume-based procurement program.Procurement and Industry Impact • Heparin is now directly exposed to China's volume-for-price procurement model. The 8th round included two major heparin products enoxaparin sodium and nadroparin calcium with 20 specifications, while the broader procurement round achieved an average price reduction of around 56%. For manufacturers, winning procurement contracts can deliver substantial hospital volume, but profitability increasingly depends on manufacturing scale, API integration and cost control.• China's National Healthcare Security Administration explicitly states that centralized-procurement products must maintain supply, and its 2024 supply-assurance policy requires selected manufacturers to sign procurement agreements and fulfill their contracted obligations; companies that fail to contract or disrupt supply can face consequences including cancellation of their selected status. This makes manufacturing capacity, API security, quality consistency and distribution capability increasingly important alongside bid price.• The procurement environment is rewarding manufacturers that can operate at scale and participate across the heparin value chain. Hepalink's 2025 results illustrate the effect: its heparin supply-chain business generated approximately RMB 4.05 billion in revenue, while finished-dose pharmaceutical products generated approximately RMB 2.99 billion; the company reported that Chinese-market product sales increased under centralized procurement even as procurement prices declined substantially.Segment AnalysisChina Heparin Market By Product Type• LMWH is the core growth and clinical-use segment in China because it combines predictable anticoagulant activity with convenient subcutaneous administration.

Chinese clinical literature notes that LMWH has increasingly replaced conventional UFH in routine anticoagulation because of its longer half-life, greater bioavailability and relatively lower risk of heparin-induced thrombocytopenia. China has developed substantial domestic expertise in LMWH production, particularly through the conversion of heparin sodium into differentiated products such as enoxaparin, nadroparin and dalteparin. This creates an important distinction between China as a raw-material supplier and China as a manufacturer of higher-value downstream anticoagulants.• UFH remains strategically important despite the shift toward LMWH. Its principal advantage in China is rapid onset, short duration and reversibility with protamine, making it valuable when clinicians need close control of anticoagulation or rapid adjustment around procedures. UFH has a particularly strong role in interventional cardiology, critical care and renal replacement therapy. Unlike LMWH, UFH can be titrated using coagulation monitoring, which makes it useful when renal function is severely impaired or when anticoagulation must be rapidly modified.

Chinese thrombosis guidance continues to recognize UFH as an important initial anticoagulant for acute thrombotic disease.• ULMWH represents a more specialized part of the Chinese heparin landscape. Its importance is linked less to broad commodity-style use and more to continued pharmaceutical innovation around molecular-size control, anticoagulant selectivity and safety. The segment is relevant to China's effort to move from basic heparin extraction toward value-added anticoagulant technologies. Compared with conventional UFH, increasingly fractionated heparin products are intended to provide more predictable pharmacological behavior and potentially more targeted anticoagulant effects.China Heparin Market By Application• The coronary artery disease segment is closely connected with China's large interventional cardiology ecosystem. Heparin is particularly relevant during procedures such as PCI, where immediate anticoagulation is required to limit thrombus formation associated with vascular intervention. UFH retains a strong procedural role because it can be administered intravenously and adjusted according to coagulation testing.

At the same time, enoxaparin has an established position among LMWH products used in selected coronary settings. Chinese PCI consensus specifically identifies UFH and LMWH among the non-oral anticoagulants available for perioperative management.• DVT is one of the most established therapeutic applications for LMWH in China. The major commercial advantage of LMWH is its ability to provide effective anticoagulation without the intensive dose adjustment normally associated with intravenous UFH. Chinese thrombosis guidance recognizes both LMWH and UFH as initial treatment options for acute DVT, while noting that LMWH is used most frequently in clinical practice.• Pulmonary embolism is an important hospital-based application because anticoagulation needs to begin rapidly once PE is strongly suspected or diagnosed. Chinese guidance recognizes parenteral anticoagulants including UFH and LMWH as initial treatment options. The 2025 Chinese pulmonary thromboembolism guidelines further demonstrate that PE management remains an active area of clinical standardization in China.

The guidelines emphasize improvements in diagnosis and treatment while noting continued differences between regions and healthcare institutions.• Kidney dialysis is one of the most distinctive heparin applications because anticoagulation is required to prevent clotting within the extracorporeal blood circuit. This gives heparin demand a recurring, procedure-driven component rather than making it dependent solely on acute thrombotic events. UFH has traditionally been particularly important in dialysis because its short half-life and established monitoring protocols allow anticoagulation to be adjusted during treatment. LMWH can also be used, creating a product-selection dynamic based on institutional protocols, patient bleeding risk and operational preferences.• Others category encompasses surgical anticoagulation, intensive care, catheter-related applications and other situations in which prevention of thrombosis is required. This segment is particularly relevant to UFH because hospitals value its rapid onset, short half-life and ability to be reversed. Heparin can also be used for maintaining extracorporeal or intravascular systems where local thrombosis would interfere with treatment.China Heparin Market By Source• Porcine-derived heparin is the dominant source underlying China's heparin ecosystem.

China's extensive pork-processing industry provides access to porcine intestinal mucosa, the principal raw material used in commercial heparin extraction. The supply-chain connection is unusually strong: Chinese manufacturers can integrate animal-material collection, crude heparin extraction, purification, pharmaceutical-grade heparin production and subsequent LMWH processing. This vertical integration gives China a structural advantage in the global heparin industry.• Bovine-derived heparin provides a source-diversification alternative to the overwhelmingly porcine-centered Chinese supply chain. Its strategic relevance increases when manufacturers or regulators seek to reduce dependence on a single animal source. Historically, Chinese Pharmacopoeia material has recognized heparin sodium as being obtainable from porcine or bovine intestinal mucosa, demonstrating that both animal sources have a regulatory and pharmaceutical history in China. However, bovine-derived heparin faces a more difficult commercial position because the Chinese heparin manufacturing infrastructure is heavily optimized around porcine material.

Moving toward bovine inputs can therefore require adjustments in sourcing, purification, validation and manufacturing processes.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Heparin Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product Type• Low Molecular Weight Heparin (LMWH)• Unfractionated Heparin (UFH)• Ultra-Low Molecular Weight Heparin (ULMWH)By Application• Coronary Artery Disease• Deep Vein Thrombosis• Pulmonary Embolism• Kidney Dialysis• OthersBy Source• Porcine-derived• Bovine-derived.